Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927758 · ClinicalTrials.gov registry record · Phase 2
Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair
A Phase 2 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00927758 is a Phase 2 study that has completed, run by Sandoz. The registered enrollment target is 105 participants.
The verdict
NCT00927758, a Phase 2 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.
Interventions
- DRUG fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927758
The ClinicalTrials.gov registry entry for NCT00927758 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg is the first listed.
NCT00927758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00927758 about?
NCT00927758 is a clinical study titled "Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair". To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines.
What is the current status of trial NCT00927758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2009-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00927758?
The interventions under investigation include: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg (DRUG).
Who is sponsoring clinical trial NCT00927758?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.